Drug Database
IN

influenza vaccine (egg-based) (Teratect)

✓ Approved

Il-Yang · 疫苗 · 疫苗

什么是 influenza vaccine (egg-based)?

influenza vaccine (egg-based) 是一种疫苗,由Il-Yang研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intramuscular (IM) Injection。

药物档案

商品名Teratect
公司Il-Yang
药物类别疫苗, 大分子
给药途径Injectable (Others), Intramuscular (IM) Injection
状态Approved

治疗适应症

influenza vaccine (egg-based) 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsInfluenza✓ Approved

相关研究文献

PubMedFrontiers in public health2026-11-18

Characteristics of adverse events of inactivated quadrivalent influenza vaccine in healthy populations: a meta-analysis based on randomized controlled trials.

Kang Liuyang L, Yang Jing J, Cheng Jingru J, Tang Shaowen S et al.

Influenza constitutes a critical global public health issue, and quadrivalent inactivated influenza vaccine (QIV) is widely used, yet systematic analyses of its adverse events (AEs) remain lacking. This meta-analysis aimed to characterize AEs following QIV vaccination in healthy populations. We searched for randomized controlled trials (RCTs) of QIV vaccination in healthy populations, extracted AE data from QIV groups, pooled incidence rates, and compared the risks of AEs between QIV and trivalent influenza vaccine (TIV) using a random-effects model. Subgroup analyses, meta-regression, and sensitivity analyses were applied to explore heterogeneity and result robustness. Publication bias was evaluated utilizing Begg's and Egger's tests. A total of 29 studies published from 2008 to 2025 were included, involving 28,410 participants with 8,197 reported AEs in total. The overall incidence of AEs after QIV vaccination in healthy populations was 43% (95% CI: 31%-54%), with an incidence of 27% (95% CI: 18%-37%) for local AEs and 20% (95% CI: 14%-26%) for systemic AEs. The incidence of SAEs was 0.96%. The QIV group showed significantly elevated risks of overall and local AEs relative to TIV (P < 0.05), while no significant differences were detected in systemic AEs and SAEs between the two groups (P > 0.05). Heterogeneity was associated with study period, study region, AE collection duration, and vaccine origin. Sensitivity analyses and publication bias analyses confirmed result stability. This study summarizes AE incidence and features after QIV in healthy populations, supporting clinical vaccination and post-vaccination safety surveillance with exploratory data. https://www.crd.york.ac.uk/PROSPERO/view/CRD420251233388, identifier CRD420251233388.

PMID 43047547
阅读全文 →
PubMedJournal of nanobiotechnology2026-11-18

Baculovirus-based production of virus-like particles for avian influenza: development, immunogenicity, and cross-protection against H5 and H7 AIVs.

He Yanjuan Y, Dong Yajing Y, Kong Dexin D, Chen Huixin H et al.

The persistent threat of H5 and H7 highly pathogenic avian influenza (HPAI) necessitates effective broad-spectrum vaccines. This study systematically evaluated the immunogenicity and protective efficacy of H5N6 virus-like particle (H5N6-VLP) vaccine and subsequently developed a trivalent VLP vaccine (H5N6-H5N8-H7N9-VLP) using the baculovirus expression system (BEVS). Production of H5N6-VLP was optimized at a multiplicity of infection (MOI) of 0.1 to achieve efficient assembly. The H5N6-VLP vaccine induced potent immune responses in specific-pathogen-free (SPF) chickens, providing 100% protection against homologous H5N6-GD154 virus when the HA titer reached 9 log2. Compared with traditional inactivated vaccines, the H5N6-VLP vaccine induced faster humoral immune responses and higher CD8⁺ T cell proportions. The HI seroconversion rate was 30% on day 7 post-immunization (0% for inactivated vaccine), reached 100% by day 10, while it was only 80% on day 14 for the inactivated vaccine. Furthermore, the protective efficacy of the H5N6-VLP vaccine was associated with increased IFN‑γ expression and elevated proportions of B cells and CD8⁺ T cells. Although both vaccines provided complete homologous protection, the H5N6-VLP vaccine showed better cross-protection against the heterologous H5N1-D889 strain (70% vs. 40%). A delayed challenge experiment further demonstrated that the H5N6-VLP vaccine induced durable immunity, with HI titers remaining above the protective threshold and 100% protection against homologous challenge at 8 weeks post-immunization. Based on these findings, a trivalent H5N6-H5N8-H7N9-VLP vaccine was developed. The trivalent vaccine induced substantial antibody responses and provided complete protection against parental and circulating strains, with efficacy comparable to a commercial inactivated vaccine and no detectable antigenic interference between components. Our findings highlight the potential of the BEVS-derived H5N6-VLP vaccine, particularly its early antibody induction, which allows rapid flock protection during acute HPAI outbreaks, and its cross-reactivity against heterologous strains. Furthermore, the trivalent vaccine formulation extends the potential application of this VLP platform for broad-spectrum HPAI control.

PMID 43046102
阅读全文 →
PubMedBMJ public health2026-11-18

Decomposition of disparities in influenza and pneumococcal vaccination coverage by immigrant status among older adults in Canada: results from the Canadian longitudinal study on aging (CLSA).

Kim Ji Yoon JY, Yang Seungmi S, Russell W Alton WA, Sulis Giorgia G et al.

Immigrant older adults in Canada have lower coverage for influenza and pneumococcal vaccinations compared with non-immigrants, yet the specific factors contributing to these disparities remain underexplored. Using data from the Canadian Longitudinal Study on Aging, we applied a non-linear Blinder-Oaxaca decomposition method to assess the contributions of demographic, socioeconomic, health-related and neighbourhood characteristics to influenza (n=23 214) and pneumococcal (n=22 235) vaccination disparities. Overall, the disparities were driven by differences in associations between characteristics and vaccination outcomes (ie, coefficient estimates), rather than by differences in distributions of characteristics (ie, covariate estimates). Some characteristics contributed to widening and others to narrowing disparities but the contributions varied by vaccine type. The combined contributions of all covariates were negative (influenza: -1.95 (95% CI -2.80 to -1.11); pneumococcal: -0.24 (95% CI -1.15 to 0.67)) suggesting that if immigrants had the same distributions of characteristics and associations between characteristics and vaccination as non-immigrants, vaccination disparities would widen. Unmeasured and/or unknown variables (ie, the intercept) (influenza: 1.67 (95% CI -24.05 to 27.38); pneumococcal: 22.60 (95% CI -3.42 to 48.61)) had a substantial role in explaining disparities in both outcomes. These results suggest that immigrants have lower vaccination coverage despite being more likely to have traits associated with a higher likelihood of vaccination, some of which were more strongly associated with vaccination for immigrants. Commonly researched determinants of vaccination do not explain the lower vaccination coverage among older Canadian immigrants. Future research should investigate additional determinants, particularly societal and structural factors, that may shape vaccination decisions differently for immigrants, focusing on individual vaccine types. Such insights will inform the development of targeted interventions to address vaccine inequities in Canada.

PMID 43047962
阅读全文 →
PubMedInfection and immunity2026-11-18

Species-specific responses of bovine and ovine macrophages to Coxiella burnetii infection.

Bauer Benjamin U BU, Jahnke Rico R, Cottineau Thierry T, Knittler Michael R MR

Cattle and sheep are reservoir hosts for Coxiella (C.) burnetii, and their role is crucial in transmitting the bacterium to humans. Therefore, understanding immune responses is essential for preventing and managing Q fever. Macrophages play a dual role in Coxiella infections. They eliminate the pathogen and serve as host cells in which it can multiply. Our comparative studies of Coxiella infection in primary bovine and ovine macrophages reveal host-specific immune responses. After Coxiella infection, cattle macrophages predominantly express inducible nitric oxide synthase (iNOS) and produce nitric oxide (NO), whereas sheep macrophages principally express indoleamine 2,3-dioxygenase 1 (IDO1). Although macrophages from both species exhibit similar infection rates, there are differences in cytokine expression. This pattern holds for both live and chemically inactivated Coxiella. In ovine macrophages, formalin-inactivated Coxiella triggers a much stronger transcriptional response for TLRs, IDO1, IL-6, IL-10, IL-12, and IL-23 than live Coxiella, suggesting a host-specific immune subversion strategy by Coxiella in sheep. For the antigen processing/presentation machinery, we found comparable induction of surface MHC and CD40 proteins in both macrophages, whereas expressions of CD11b, CD80, and CD86 are higher in ovine than in bovine macrophages, indicating different strategies for macrophage activation. Consistent with this, the regulatory effects of self-produced NO on MHC II antigen presentation via transcriptional regulation are observed in cattle but not in sheep macrophages. Our current findings highlight the immunological traits of closely related reservoir host species in shaping cellular responses to Coxiella and have significant implications for understanding disease progression, susceptibility, and treatment.

PMID 43049707
阅读全文 →
PubMedCureus2026-11-18

Maternal Vaccine Receipt, Intentions, and Refusal Among Pregnant Women Attending Antenatal Care in Panama City: A Cross-Sectional Study.

Lucas Quintero Ana A, DeAntonio Rodrigo R, Escobar Luis L, Flores Luis Alberto LA et al.

Background/objectives Maternal vaccination surveys often combine willingness and receipt, potentially obscuring differences between these measures. We quantified self-reported vaccine receipt, intention without receipt, complete reported receipt, and refusal in an urban Panamanian convenience sample and examined their relationship with vaccination recommendation. Methods We analyzed an anonymous cross-sectional survey completed from March 26 to July 25, 2026, by 204 pregnant women aged 18 years or older recruited in health-related settings in Panama City. Self-reported receipt meant reporting at least one maternal vaccine during the current pregnancy. Intention without receipt meant planning at least one vaccine without reporting receipt of any specific vaccine. Complete reported receipt was the independent response "already received all," rather than verified completion of a vaccination schedule. Modified Poisson regression with robust variance estimated prevalence ratios (PRs). A secondary, post hoc evaluation examined six rating items without claiming formal questionnaire validation. Results The number of women who chose self-reported receipt was 128/204 (62.7%; exact 95% confidence interval (CI), 55.7-69.4), while the composite of receipt or intention was 190/204 (93.1%). Intention without receipt was reported by 62/204 (30.4%), complete reported receipt by 41/204 (20.1%), and refusal with coexisting receipt or intention by 92/204 (45.1%). Four participants reporting complete receipt did not report any vaccine-specific receipt. Refusal was reported for COVID-19 by 96/204 (47.1%), influenza by 11/204 (5.4%), tetanus, diphtheria, and acellular pertussis (Tdap) by 8/204 (3.9%), and respiratory syncytial virus (RSV) by 7/204 (3.4%). Receipt was reported by 126/172 (73.3%) participants with a vaccination recommendation versus 2/32 (6.2%) without one (adjusted PR, 11.28; 95% CI, 2.95-43.17). Three-item standardized Cronbach's alpha values were 0.699 and 0.728, with substantial ceiling effects and an unstable two-factor solution. Conclusions In this convenience sample, stated acceptance coexisted with the absence of reported receipt and vaccine-specific refusal. Recommendation was associated with receipt, but the estimate was imprecise and noncausal. These findings are not population estimates and support reporting recommendation, intention, receipt, and refusal separately. Intention without receipt does not establish subsequent failure to vaccinate.

PMID 43048589
阅读全文 →
PubMedAmerican journal of cancer research2026-11-18

Advancements in vaccines against cancer stem cells (CSCs).

Aayush, Talebiashtiany Yasaman Y, Abubakar Bobbo Khadijat K, Manogaran Motharasan M et al.

Cancer stem cells (CSCs) are a significant problem in cancer treatment due to their ability to self-renew, differentiate, and migrate, thus initiating and maintaining extensive support for metastasis. One way to eliminate CSCs is by using CSC-specific targeting vaccines, which mainly utilise their unique CSC-associated antigens. The current potential vaccines against the CSCs are the Dendritic Cell (DC)-based vaccine, Nanoparticle (NP)-based vaccine, and iPSC (Induced Pluripotent Stem Cell)-based vaccine. Potential vaccines/immunotherapies, such as GM-CSF Surface-Modified vaccines and VLP-based xCT immunotherapy, are also discussed. This review aims to highlight the progress in vaccinology against CSCs and the current limitations of these vaccines, such as the tumour microenvironment (TME) and a higher proliferation rate responsible for the low efficacy of anti-CSC vaccines.

PMID 43048158
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多influenza vaccine (egg-based)